Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Literature DB >> 17206118

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Alan Hatfield, Samantha Owen, Paul Richard Pilot.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 17206118 DOI： 10.1038/nm0107-13a

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

Review 1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: Intern Emerg Med Date: 2011-12-13 Impact factor: 3.397

Review 2. Eosinophilic myeloproliferative disorders.

Authors: Amy D Klion
Journal: Hematology Am Soc Hematol Educ Program Date: 2011

3. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.

Authors: Nicola Sgherza; Antonella Vita Russo Rossi; Paolo Colonna; Paola Carluccio; Mario Delia; Giorgina Specchia
Journal: Int J Hematol Date: 2013-07-24 Impact factor: 2.490

Review 4. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.

Authors: Grazia Casavecchia; Maurizio Galderisi; Giuseppina Novo; Matteo Gravina; Ciro Santoro; Eustachio Agricola; Silvana Capalbo; Stefano Zicchino; Matteo Cameli; Luisa De Gennaro; Francesca Maria Righini; Ines Monte; Carlo Gabriele Tocchetti; Natale Daniele Brunetti; Cristian Cadeddu; Giuseppe Mercuro
Journal: Heart Fail Rev Date: 2020-05 Impact factor: 4.214

5. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Authors: Hossein A Ghofrani; Nicholas W Morrell; Marius M Hoeper; Horst Olschewski; Andrew J Peacock; Robyn J Barst; Shelley Shapiro; Heiko Golpon; Mark Toshner; Friedrich Grimminger; Steve Pascoe
Journal: Am J Respir Crit Care Med Date: 2010-06-25 Impact factor: 21.405

Review 10. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.

Authors: Shelby D Reed; Kevin J Anstrom; Yanhong Li; Kevin A Schulman
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Review 1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Review 2. Eosinophilic myeloproliferative disorders.

3. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.

Review 4. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.

5. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Review 6. Chronic myelogenous leukemia: treatment and monitoring.

Review 7. Imatinib: a review of its use in the management of gastrointestinal stromal tumours.

Review 8. Imatinib: a review of its use in chronic myeloid leukaemia.

9. Cardiotoxicity associated with targeted cancer therapies.

Review 10. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.